Amcalon Corporation - XL-6
Paper published:
In the first quarter of 2007, Amcalon Corporation released a paper to the Scientific and Medical Journal, describing a breakthrough in decelerating the onset of Necro-Mortosis
Our company spokesperson said , "The tests are still in their preliminary stages. We need to duplicate the effect in many ways before moving forward with development of a possible vaccine." The paper stated that a human subject was administered the inhibitor referred to as XL6, after it became known that he had contracted the virus. "Typically an exposed person will begin showing signs of decay and mortification within one or two days. This subject was able to offset the effects of Necro-mortosis for seven days. During which time he was in a healthy and stable condition."
Unfortunately, on the seventh day, he developed a sever flu. The virus attacked his central nervous system shortly thereafter. He was terminated shortly after reanimation on the eight day.
Test results:
Studies in Berlin suggest that Antiviral test drugs can interrupt the process by which a virus reproduces at several stages. The inhibitor XL-6, for example, prevents the virus particle from opening after it enters the cell and can inhibit the manufacture of virus proteins. It also stop the virus from exiting the cell.
Stem cell research:
President Bush recently signed a legislation banning the use of three of the five listed stem cells needed to proceed with development of the XL6 Mortosis inhibitor.
To use an embryonic stem cell, scientists must have access to an embryo outside the woman’s body. The embryo is only allowed to develop for a few days before termination. Researchers isolate and remove the stem cell from the embryo thereby destroying the embryo in the process.
Phase two testing
XL-6 has now entered phase two preliminary testing In Germany, Spain and Peru. We also intend to introduce testing (as results progress) in the U.K., Japan and South Korea.
In the first quarter of 2007, Amcalon Corporation released a paper to the Scientific and Medical Journal, describing a breakthrough in decelerating the onset of Necro-Mortosis
Our company spokesperson said , "The tests are still in their preliminary stages. We need to duplicate the effect in many ways before moving forward with development of a possible vaccine." The paper stated that a human subject was administered the inhibitor referred to as XL6, after it became known that he had contracted the virus. "Typically an exposed person will begin showing signs of decay and mortification within one or two days. This subject was able to offset the effects of Necro-mortosis for seven days. During which time he was in a healthy and stable condition."
Unfortunately, on the seventh day, he developed a sever flu. The virus attacked his central nervous system shortly thereafter. He was terminated shortly after reanimation on the eight day.
Test results:
Studies in Berlin suggest that Antiviral test drugs can interrupt the process by which a virus reproduces at several stages. The inhibitor XL-6, for example, prevents the virus particle from opening after it enters the cell and can inhibit the manufacture of virus proteins. It also stop the virus from exiting the cell.
Stem cell research:
President Bush recently signed a legislation banning the use of three of the five listed stem cells needed to proceed with development of the XL6 Mortosis inhibitor.
To use an embryonic stem cell, scientists must have access to an embryo outside the woman’s body. The embryo is only allowed to develop for a few days before termination. Researchers isolate and remove the stem cell from the embryo thereby destroying the embryo in the process.
Phase two testing
XL-6 has now entered phase two preliminary testing In Germany, Spain and Peru. We also intend to introduce testing (as results progress) in the U.K., Japan and South Korea.
